Veteran investor and executive with broad experience in corporate finance, strategic partnerships and operational leadership. Denise Reinert brings a market-focused approach to sourcing growth-stage and turnaround opportunities across technology, healthcare and services. She has led capital raises, portfolio governance and operational transformations while working with private equity and venture-backed companies. Background combines senior roles in corporate development and operating teams with an education oriented to finance and management. Typical focus: growth equity, cross-border expansion and board-level oversight.
Veteran investor and executive with broad experience in corporate finance, strategic partnerships and operational leadership. Denise Reinert brings a market-focused approach to sourcing growth-stage and turnaround opportunities across technology, healthcare and services. She has led capital raises, portfolio governance and operational transformations while working with private equity and venture-backed companies. Background combines senior roles in corporate development and operating teams with an education oriented to finance and management. Typical focus: growth equity, cross-border expansion and board-level oversight.
Adopts a market-driven growth equity and turnaround orientation, prioritizing scalable technology, healthcare and services franchises with clear paths to operational improvement. Prefers minority-to-control investments where capital and board guidance accelerate cross‑border expansion, revenue scaling and margin restoration. Underwrites deals with fundamental diligence, conservative leverage and milestone-based capital deployment, emphasizing hands-on portfolio governance, operational playbooks and 3–7 year value-creation horizons to de-risk exits.
Adopts a market-driven growth equity and turnaround orientation, prioritizing scalable technology, healthcare and services franchises with clear paths to operational improvement. Prefers minority-to-control investments where capital and board guidance accelerate cross‑border expansion, revenue scaling and margin restoration. Underwrites deals with fundamental diligence, conservative leverage and milestone-based capital deployment, emphasizing hands-on portfolio governance, operational playbooks and 3–7 year value-creation horizons to de-risk exits.
| Trades 1365 | Longs Won 922/1365 67% | Profit Factor 25.49 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $537,279.82 |
| Average Win $94,288.17 | Best Trade (Jul 17) $10.36M | Sharpe Ratio -12.21 |
| Average Loss -$7,700.01 | Worst Trade (Jul 15) -$438,949.93 | Z-Score 7.79 (100%) |
| Commissions $0 | Avg. Trade Length 1y 6m 1w 5d | Expectancy $61,188.71 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 50,000 | 45,000 | 40,000 | 35,000 | 30,000 | 25,000 | 20,000 | 15,000 | 10,000 | 5,000 |